Drug discovery and development – Page 2
-
OpinionIs it cold in here?
Labs in Delhi, Aberdeen and Arizona will have different ideas of ‘room temperature’
-
OpinionCrispr therapies will change medicine but there will be challenges along the way
The first treatments making use of Crispr gene editing may suffer some early hiccups
-
ResearchAI tool dramatically reduces computing power needed to find protein-binding molecules
New protocol is up to 10 million times faster than current docking-based methods
-
ResearchCrystal structure prediction reaches new heights with axitinib
Computational strategy predicts complex polymorphs and distinguishes salts from co-crystals
-
BusinessUK agrees higher drug prices to secure zero-tariff deal with US
NHS could pay up to 25% more for innovative drugs, but exports will be tariff free for three years
-
OpinionWhat’s on your lab technology wish list?
Once-magical tools are now mundane. What will the next miracles be?
-
ResearchRevived claims that antibiotics don’t kill bacteria with reactive oxygen prove controversial
Researchers say that multiple lines of evidence for hypothesis have now been undermined
-
NewsCould Crispr cure HIV?
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication
-
OpinionA robotic helping hand
Mechanical labmates are making huge progress, but there are still big challenges to overcome
-
ResearchAI-designed antibodies target antigens with atomic precision
Epitope-binding proteins designed from scratch by generative AI model
-
ResearchAI cut development time of antibiotic that spares gut-friendly bacteria by two years
Animal tests show promise to target invasive strain of E. coli but approval for use in humans is still years away
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
ResearchNanobodies from alpacas and llamas could hold the key to a universal antivenom
Novel nanobody mix protects against 17 African snake species
-
BusinessNovartis spends on deals to offset patent losses
$12 billion Avidity acquisition is the latest pipeline-pumping transaction
-
ResearchThis fragment-based drug discovery library is designed to be sociable
Study targets a key bottleneck in hit to lead optimisation by designing fragments that are both structurally diverse and easy to elaborate
-
WebinarSYNTHIA for chemists: faster route design
Discover how SYNTHIA accelerates retrosynthesis by helping chemists design, compare and refine routes with customisable filters and commercial building blocks
-
ResearchUltrapotent thrombin inhibitor combines peptide fragments from a trio of blood-sucking organisms
Hybrid molecule featuring leech, tsetse fly and flea peptide fragments binds thrombin at three sites
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Learn about the latest technology to accelerate the design of cancer treatments
-
BusinessArvinas and Pfizer seek a new home for protein degrader drug
Companies offer bifunctional cancer drug vepdegestrant to new partners after disappointing trial results
-
BusinessNovo Nordisk’s new chief cuts 9000 jobs
Danish firm shifts strategy after struggling to capitalise on its weight loss drugs